Sepracor (SEPR) is expected to report Q4 earnings on Wednesday, January 28 after market close with a conference call scheduled for January 29 at 8:30 am ET.
Analysts are looking for a profit of 56c on revenue of $353M. The consensus range for EPS is 45c-66c, with a revenue range of $337M-$378M, according to First Call. For Q3, the company reported EPS 17c vs. consensus of 14c and revenue $308M vs. consensus of $292M.
Positive catalysts this quarter could come from sales growth in Brovana, a COPD treatment, as well as Omnaris and Alvesco. Negative drivers for this quarter's results could include increased competition for Lunesta and pressure on sales of Xopenex. On January 14, Sepracor was upgraded to Neutral from Underperform at BofA/Merrill.